Michael Gutch, Ph.D., joins Entact Bio having previously served as Executive Vice President, Chief Financial Officer for Noema Pharma AG which was focused on developing several product candidates for debilitating CNS disorders and where he helped raise a 103M CHF series B financing in 2023. Previously, Mike was Chief Business Officer and Chief Financial Officer at Entasis Therapeutics, which developed antibiotics for drug-resistant infections, and where he led their 2018 IPO and strategic partnerships on their two lead programs. Dr. Gutch was also Executive Director of Corporate Development and Head of Equities at AstraZeneca, during which time he oversaw the formation of Entasis as an independent company. Prior to this, Dr. Gutch worked in venture capital investment, first as a principal of Lilly Ventures, the corporate venture arm of Eli Lilly & Company, then as investment director of HIG BioVentures at the investment firm HIG BioVentures, and finally as Managing Director at MedImmune Ventures, the corporate venture arm of AstraZeneca. Dr. Gutch was previously a member of the Board of Directors of Albireo Pharma (Nasdaq: ALBO) which sold to Ipsen SA in March 2023. He received his Ph.D. in Molecular Pathology from the State University of New York at Stony Brook and his MBA in Finance from Indiana University.